证券代码：600668 证券简称：尖峰集团 公告编号：临 2024-037 浙江尖峰集团股份有限公司（以下简称"公司"）已于 2024 年 10 月 30 日 发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 12 月 09 日下午 14:00-15:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交 流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 浙江尖峰集团股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 12 月 02 日(星期一) 至 12 月 06 日(星 ...

Financial Performance - The company's operating revenue for Q3 2024 was CNY 66,321.36 million, a decrease of 2.96% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was CNY 2,293.82 million, an increase of 36.45% year-on-year[2]. - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was CNY 2,048.72 million, up 78.97% compared to the same period last year[2]. - Year-to-date net profit attributable to shareholders decreased by 45.06% to CNY 7,056.23 million compared to the same period last year[2]. - Basic earnings per share for Q3 2024 were CNY 0.0667, an increase of 36.45% year-on-year[4]. - Net profit for the first three quarters of 2024 was CNY 83,710,032.76, a decline of 34.9% compared to CNY 128,529,994.42 in the same period of 2023[18]. - The total comprehensive income for the third quarter of 2024 was CNY 53,847,582.03, a decrease from CNY 100,923,933.98 in the same period of 2023[20]. - The net profit attributable to the parent company was CNY 40,699,801.77, compared to CNY 100,826,634.01 in the previous year, reflecting a significant decline[20]. - Basic and diluted earnings per share for the third quarter were CNY 0.21, down from CNY 0.37 in the same quarter of 2023[20]. Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 708,708.72 million, a slight increase of 0.56% from the end of the previous year[4]. - The total assets as of the end of Q3 2024 were CNY 7,087,087,169.65, an increase from CNY 7,047,279,717.07 at the end of Q3 2023[16]. - Total liabilities increased to CNY 1,679,218,091.03 from CNY 1,578,751,464.77 year-over-year, representing an increase of 6.36%[16]. - The company’s total equity decreased to CNY 5,407,869,078.62 from CNY 5,468,528,252.30, a decline of 1.11%[16]. Cash Flow - The cash flow from operating activities for the year-to-date period increased by 163.05% to CNY 14,642.89 million compared to the same period last year[8]. - Cash flow from operating activities generated a net cash inflow of CNY 146,428,901.46, an increase from CNY 55,665,062.08 in the previous year[21]. - Cash flow from investing activities resulted in a net outflow of CNY 68,024,819.82, improving from a net outflow of CNY 168,239,495.94 in the same period last year[22]. - Cash flow from financing activities showed a net outflow of CNY 45,189,431.18, compared to a net outflow of CNY 11,241,202.35 in the previous year[22]. - The total cash and cash equivalents at the end of the period were CNY 214,907,185.93, down from CNY 243,654,619.48 at the end of the same period in 2023[22]. - The company received CNY 196,000,000.00 in cash from borrowings during the third quarter, compared to CNY 316,000,000.00 in the same period last year[22]. - The company reported cash receipts from sales of goods and services amounting to CNY 2,189,518,886.34, a decrease from CNY 2,355,336,830.71 in the previous year[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,382[9]. - The largest shareholder, Jinhua Tongji State-owned Assets Investment Co., Ltd., holds 55,564,103 shares, accounting for 16.15% of total shares[12]. - The company has no significant changes in the shareholding structure of the top 10 shareholders compared to the previous period[11]. - There are no indications of related party transactions among the top shareholders[10]. Operational Insights - The company attributed the increase in Q3 net profit to the improved profitability of its subsidiary's mechanism sand aggregate business[7]. - The company has not reported any significant new strategies or product developments in the current quarter[13]. Costs and Expenses - Total operating revenue for the first three quarters of 2024 was CNY 2,022,022,292.40, a decrease of 2.06% compared to CNY 2,064,631,835.35 in the same period of 2023[16]. - Total operating costs for the first three quarters of 2024 were CNY 1,960,325,832.43, down from CNY 1,986,762,089.62 in the previous year, reflecting a decrease of 1.34%[16]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 71,993,537.74, compared to CNY 84,057,891.93 in the previous year, indicating a decrease of 14.3%[18]. - The company reported a decrease in sales expenses to CNY 133,225,980.28 from CNY 151,313,015.39, a reduction of 11.93%[18]. Inventory and Receivables - Accounts receivable decreased to ¥253,102,012.73 from ¥267,256,723.29 year-over-year[14]. - Inventory increased to ¥426,628,543.08 from ¥394,608,084.43 year-over-year[14]. - The company's non-current assets include long-term equity investments valued at ¥1,772,836,923.48, down from ¥1,844,039,849.77[14]. - The total current assets as of September 30, 2024, are ¥1,147,431,695.32, compared to ¥1,100,430,619.82 at the end of 2023[14]. - The deferred income tax assets rose to CNY 67,666,548.72 from CNY 58,843,975.85, reflecting an increase of 14.5%[16].

证券代码：600668 证券简称：尖峰集团 公告编号：2024-035 浙江尖峰集团股份有限公司 二、报告期内分产品经营数据 单位：万元 币种：人民币 | 产品 | | 主营业务收入 | | | 主营业务成本 | | | 毛利率 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 2024 年 | 2023 年 | 增长率 | 2024 年 | 2023 年 | 壇长 | 2024 | 2023 | | | | 1-9 | 1-9 月 | (%) | 1-9 | 1-9 | 版 | 年 1-9 | 年 1-9 | 增减百分点 | | | | | | | | (%) | 月(%) | 月(%) | | | 水泥 | 77.931.66 | 105,418.88 | -26.07 | 64.509.54 | 83.333.66 | -22.59 | 17.22 | 20.95 | 减少 3.73 个 | | | | | | | | | | | 百分点 | | 机制砂 | 12.057.85 | | 100.00 | 7,968 ...

本次获得玻璃酸钠滴眼液《药品注册证书》，标志着尖峰药业及子公司尔 婴公司具有进行该药品生产、销售的资格，将进一步丰富公司的产品线， 有助于提升公司医药业务的竞争力。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的前期研发及研制、报批到投产的周期长、投入大、环节多，而且 药品获得注册证书后的生产和销售也容易受到国家政策、市场环境等因 素的影响，敬请广大投资者注意投资风险。 上市许可持有人：浙江尔婴药品有限公司 生产企业：浙江尖峰药业有限公司 证书编号：2024S02397 药品注册标准编号：YBH22562024 药品有效期：18 个月 药品批准文号：国药准字 H20249050 药品批准文号有效期：至 2029 年 10 月 15 日 审批结论： 证券代码：600668 证券简称：尖峰集团 编号：临 2024-034 浙江尖峰集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）全资子 ...

证券代码：600668 证券简称：尖峰集团 公告编号：临 2024-033 浙江尖峰集团股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 09 月 26 日(星期四) 至 10 月 09 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jfjtsmh@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 浙江尖峰集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 28 日发 布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年 半年度经营成果、财务状况，公司计划于 2024 年 10 月 10 日下午 14:00-15:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网 ...

证券代码：600668 证券简称：尖峰集团 公告编号：2024-032 浙江尖峰集团股份有限公司 关于公司 2024 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业 信息披露指引第七号——医药制造》及《关于做好上市公司 2024 年半年度报告 披露工作的通知》相关要求，因公司目前涉及医药制造行业，现将公司 2024 年 半年度主要经营数据披露如下： 一、报告期内分行业经营数据 单位：万元 币种：人民币 | | 主营业务收入 | | | 主营业务成本 | | | 毛利率 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 2024 年 | 2023 年 | 增长率 | 2024 年 | 2023 年 | 增长率 | 2024 | 2023 年 | 增减 | | | 月 1-6 | 月 1-6 | （%） | 月 1-6 | 月 1-6 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2024-030 浙江尖峰集团股份有限公司 十二届4次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 （一）本次董事会会议的召集、召开符合有关法律、法规及《公司章程》 的相关规定。 （二）2024 年 8 月 16 日，公司以传真、电子邮件及专人送达的方式发出了 本次董事会会议通知。 董事会 二〇二四年八月二十八日 二、董事会会议审议情况 1、通过了《2024 年半年度报告及其摘要》 经审议与表决，董事会通过了《2024 年半年度报告及其摘要》。 表决结果：9 票同意、0 票反对、0 票弃权。 2024 年半年度报告全文及摘要详见上海证券交易所网（www.sse.com.cn）。 三、相关附件 公司第十二届董事会第 4 次会议决议 特此公告 浙江尖峰集团股份有限公司 （三）2024 年 8 月 26 日，本次董事会会议以通讯表决的方式召开。 （四）公司现有九名董事，全体董事出席了会议。 1 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 135,880.87 million, a decrease of 1.62% compared to CNY 138,118.63 million in the same period last year[12]. - The net profit attributable to shareholders of the listed company was CNY 4,762.41 million, down 57.33% from CNY 11,162.18 million year-on-year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 3,800.96 million, a decrease of 62.62% compared to CNY 10,169.71 million in the previous year[13]. - Basic earnings per share decreased by 57.33% to CNY 0.1384 compared to the same period last year[14]. - Diluted earnings per share also decreased by 57.33% to CNY 0.1384 compared to the same period last year[14]. - The weighted average return on equity dropped to 0.94%, down from 2.13% in the same period last year[14]. - The company's net profit for the first half of 2024 was CNY 47.62 million, a significant year-on-year decline of 57.33%[24]. - The total profit for the first half of 2024 was CNY 82,577,659.30, down from CNY 139,097,919.15 in the first half of 2023, marking a decrease of around 40.4%[78]. Cash Flow and Assets - The net cash flow from operating activities increased by 122.05%, reaching CNY 6,120.96 million, compared to CNY 2,756.54 million in the same period last year[13]. - The company's cash and cash equivalents at the end of the reporting period were CNY 23,958.68 million, an increase of 13.40% from CNY 21,127.88 million at the end of the previous year[26]. - The company's cash and cash equivalents increased to ¥239,586,847.56 as of June 30, 2024, up from ¥211,278,795.28 on December 31, 2023, representing a growth of approximately 13.5%[71]. - The total assets at the end of the reporting period were CNY 701,262.25 million, a decrease of 0.49% from CNY 704,727.97 million at the end of the previous year[13]. - The company's total assets as of June 30, 2024, amounted to CNY 4,528,914,153.81, an increase from CNY 4,493,259,088.30 at the end of 2023[76]. - The company's total liabilities increased to ¥2,695,505,000.00, up from ¥2,438,000,000.00, indicating a rise of approximately 10.6%[72]. Market and Industry Trends - Total cement production for large-scale enterprises was 850 million tons, a decrease of 10.0% year-on-year, marking the lowest level since 2011[19]. - Real estate development investment reached CNY 5.25 trillion, down 10.1% year-on-year, with funds available for real estate development decreasing by 22.6%[19]. - The cement market is experiencing a trend of "declining demand, low price fluctuations, and continuous industry losses" in the first half of 2024[19]. - The pharmaceutical manufacturing industry in China achieved operating revenue of CNY 1,235.27 billion, a year-on-year decrease of 0.9%, while total profit reached CNY 180.59 billion, a year-on-year increase of 0.7%[21]. Operational Developments - The company is focusing on optimizing operations and reducing costs, implementing benchmark management and fine management to enhance efficiency[24]. - The company is expanding its product lines in pharmaceuticals, including antibiotics and oncology drugs, while also developing health products like herbal extracts[17]. - The company has established new production lines for mechanism sand and aggregates, with the production line in Hubei already operational[17]. - The company is actively pursuing technological upgrades to improve production efficiency and reduce carbon emissions, including multiple technical transformation projects[24]. - The company has completed significant upgrades in its pharmaceutical segment, including the installation of hydrogen peroxide transfer chambers and X-ray detection systems, enhancing production standards and product quality[25]. Risk Management - The company has disclosed potential risks in detail in the management discussion and analysis section of the report[3]. - The report includes a forward-looking statement risk declaration, indicating that future plans and development strategies do not constitute a substantive commitment to investors[3]. - The company is exposed to risks from economic cycles, with its construction materials business closely tied to national economic growth and fixed asset investment[37]. - Energy price fluctuations pose a risk, as coal and electricity are significant cost components in cement production[37]. - The pharmaceutical sector faces risks from policy changes and increased market competition, impacting profitability[37]. Environmental and Compliance Efforts - The company is committed to promoting green factory initiatives and has received recognition for its efforts in establishing national-level green factories[40]. - The company has established pollution control facilities with a design capacity of 800,000 m³/h for SO2 and NOX treatment systems at its major plants[47]. - The company has implemented new production processes and environmental management systems to comply with stricter safety and environmental regulations[40]. - The company has achieved a B-level recognition from the Hubei Provincial Ecological Environment Department for its environmental performance[54]. - The company has established a comprehensive environmental management system, integrating monitoring data into its MES system for better oversight[54]. Corporate Governance - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for this reporting period[3]. - There are no non-operating fund occupations by controlling shareholders or other related parties[3]. - The company has ensured that all related transactions adhere to market principles and legal procedures to protect the interests of minority shareholders[59]. - The company reported a total of 670.11 million RMB in related party transactions during the reporting period, with significant transactions including 435.91 million RMB in sales and 112.24 million RMB in purchases[62]. Research and Development - The company has established a "4+2" new drug research and development strategy, aiming to enhance the quality and efficiency of new drug development through collaboration with renowned research institutions[38]. - The company has initiated the construction of a production base for pharmaceutical intermediates and chemical raw materials in Anhui, aiming for an integrated supply chain[38]. - Research and development expenses increased to CNY 49,206,647.72 in the first half of 2024, compared to CNY 55,187,579.78 in the same period of 2023, indicating a reduction of approximately 10.7%[78].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600668 证券简称：尖峰集团 编号：临 2024-031 浙江尖峰集团股份有限公司 十一届 3 次监事会会议决议公告 一、监事会会议召开情况 （一）本次监事会会议的召集、召开符合有关法律、法规及《公司章程》 的相关规定。 （二）2024 年 8 月 16 日，公司以传真、电子邮件及专人送达的方式发出了 本次监事会会议通知。 （三）2024 年 8 月 26 日，本次监事会会议以通讯表决的方式召开。 （四）公司现有五名监事，全体监事出席了会议。 二、监事会会议审议情况 通过了《2024 年半年度报告及其摘要》 会议经审议与表决，通过了该议案。 表决结果：5 票同意、0 票反对、0 票弃权 2024 年半年度报告全文及摘要详见上海证券交易所网（www.sse.com.cn）。 三、相关附件 公司第十一届监事会第 3 次会议决议 特此公告 浙江尖峰集团股份有限公司 监事会 二〇二四年八月二十八日 1 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2024-029 浙江尖峰集团股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙 江尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局核准签 发的盐酸奥洛他定滴眼液《药品补充申请批准通知书》（通知书编号：2024B03157）， 现将相关情况公告如下： 药品名称：盐酸奥洛他定滴眼液 剂型：眼用制剂 规格：0.1%（0.4ml：0.4mg，以 C21H23NO3计） 1 一、化学仿制药的基本情况 本次尖峰药业获得盐酸奥洛他定滴眼液《药品补充申请批准通知书》， 标志着尖峰药业在原批准规格 0.1%（5ml：5mg，以 C₂₁H₂₃NO₃计）基础 上，获得了 0.1%（0.4ml：0.4mg，以 C21H23NO3计）规格（以下简称：单 剂量）盐酸奥洛他定滴眼液的生产、销售资格，将进一步丰富尖峰药业 的产品种类，有助于提升公司 ...